logo-loader
Go Ahead Group

Go-Ahead Group awarded Bavarian rail contract

The new network links to three stations that Go-Ahead will be serving from 2019 through its other contracts in Baden-Württemberg

1544608172_Untitled-design-(18).jpg
Due to kick off in 2023, the 12-year franchise is the fifth network that Go-Ahead's Germany company Go-Ahead Bus and Bahn, has been awarded

Go-Ahead Group (LON:GOG) said it had been awarded lot 1 of the `Augsburger Netze´ routes by the Bavarian rail authority and the Baden-Wurttemberg public transport authority.

The bus and rail group said this network links to three stations that Go-Ahead will be serving from 2019 through its other contracts in Baden-Württemberg.

READ: UK rail industry faces upheaval as MPs call for reforms after travel chaos at Govia Thameslink Railway

The contract will consist of 56 electrical trains, which will run on a network of 7.4mln train kilometres per year, the transport firm said.

Due to kick off in 2023, the 12-year franchise is the fifth network that Go-Ahead's Germany company, Go-Ahead Bus and Bahn, has been awarded and will extend its German business to some 20mln train kilometres per year. The other contracts start in 2019and 2021.

"This network complements our existing contracts in the region and builds on our desire to provide end-to-end journeys. Our growing local team continues to look for opportunities in the region as part of our strategy to build a long-term German transport business,” Go-Ahead CEO David Brown said in a statement.

Shares in Go-Ahead were 1.3% up at 1,592.0p in early trade.

Quick facts: Go Ahead Group

Price: £19.67

Market: LSE
Market Cap: £848.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan 'driving research for novel drug development for rare diseases'

Proactive London sits down with Open Orphan PLC's (LON:ORPH) chief operating officer Maurice Treacy. Treacy discusses how he became involved with Open Orphan and his ambitions for the firm's health data initiative. ''Many rare diseases aren't known or badly diagnosed ... but rare isn't...

13 hours, 43 minutes ago

RNS

Employee Benefit Trust Share Purchase

15 hours, 3 minutes ago

Director/PDMR Shareholding

3 days, 13 hours ago

Director Declaration

1 week, 5 days ago

Total Voting Rights

2 weeks, 4 days ago

Holding(s) in Company

2 weeks, 6 days ago

Holding(s) in Company

3 weeks ago

2 min read